UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.     )*

CHEMOKINE THERAPEUTICS CORP.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

16383P107

                                (CUSIP Number)                                 

December 31, 2004

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP Number 16383P107

Page 2 of 5

1.	Name of Reporting Person S.S. or I.R.S. Identification No. of Reporting Person             Pharmaceutical Product Development, Inc.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a)  ¨ (b)  ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization             North Carolina

Number of Shares Beneficially Owned By Each Reporting Person With:   5.    Sole Voting Power                 2,500,000   6.    Shared Voting Power                 0   7.    Sole Dispositive Power                 2,500,000   8.    Shared Dispositive Power                 0

9.	Aggregate Amount Beneficially Owned by Each Reporting Person             2,500,000
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	¨
11.	Percent of Class Represented by Amount in Row (9)             7.9%
12.	Type of Reporting Person (See Instructions)             CO

CUSIP Number 16383P107

Page 3 of 5

Item 1	(a).	Name of Issuer Chemokine Therapeutics Corp. (the “Issuer”)
Item 1	(b).	Address of the Issuer’s Principal Executive Office 2386 East Mall Street, Suite 208 University of British Columbia Vancouver, British Columbia V6T1Z3
Item 2	(a).	Name of Person Filing Pharmaceutical Product Development, Inc. (“PPD”)
Item 2	(b).	Address of the Filing Person’s Principal Business Office: The address of the principal business office of PPD is: 3151 South 17th Street Wilmington, North Carolina 28412
Item 2	(c).	Place of Organization North Carolina
Item 2	(d).	Title of Class of Securities Common Stock
Item 2	(e).	Cusip Number 16383P107
Item 3.	Filing Pursuant to Rules 13d-1(b) or 13d-2(b) Not Applicable

CUSIP Number 16383P107

Page 4 of 5

Item 4.	Ownership
	(a)	Amount Beneficially Owned: See Row (9) on Page 2. Reported share ownership on this Schedule 13G represents amounts beneficially owned by PPD as of the date of the event requiring the filing of this report. These shares include (i) 2,000,000 shares of the Issuer’s common stock issuable upon conversion of 2,000,000 shares of the Issuer’s Series A preferred stock held by PPD, and (ii) 500,000 shares of the Issuer’s common stock issuable upon exercise of share purchase warrants held by PPD.
	(b)	Percent of Class: See Row (11) on Page 2.
	(c)	Sole Power vs. Shared Power to Vote and Dispose of Shares: See Rows (5)-(8) on Page 2.
Item 5.	Ownership of Five Percent or Less of a Class Not Applicable
Item 6.	Ownership of More than Five Percent on Behalf of Another Person Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not Applicable
Item 8.	Identification and Classification of Members of the Group Not Applicable
Item 9.	Notice of Dissolution of Group Not Applicable

CUSIP Number 16383P107

Page 5 of 5

Item 10. Certification After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated:

February 1, 2005

Pharmaceutical Product Development, Inc.
By:	/s/ B. Judd Hartman	(SEAL)
Name:	B. Judd Hartman
Title:	General Counsel